In addition, silencing BCL9L impaired glioma cell proliferation, whereas overexpressing BCL9L strengthened it, both in vitro (Figure 2D and Supplementary Figure 1E) and in vivo (Figure 2E and Supplementary Figure 1F). The gene discussed is BCL9L; the disease is central nervous system cancer.